Drugs / Aprotonin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00156520 | Mar → Sep 2005 | hemorrhagic disease | University of Rochester | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aprotonin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00156520 ↗ |
| Route | Intravenous | “receive either epsilon aminocaproic acid (EACA) or aprotonin intravenously” NCT00156520 ↗ |